Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty: A real-world analysis
PLOS One · 2025
DOI: 10.1371/journal.pone.0330434 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Hsien-Yuan Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Cilostazol, Angioplasty, Peripheral Arterial Disease, Lower Extremity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chung Shan Medical University Hospital.
Abstract (Originalsprache)
Background
Cilostazol has been shown to improve walking distance in patients with lower extremity arterial disease (LEAD) and may reduce restenosis after revascularization. However, its long-term prognostic impact in real-world settings remains underexplored.
Methods
We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database (2012–2022). We included stable LEAD patients who had undergone percutaneous transluminal angioplasty (PTA) and remained event-free for 1 year. Stabilized inverse probability of treatment weighting (IPTW) was applied to adjust for baseline confounders. The study aimed to evaluate the effect of cilostazol on major adverse cardiovascular events (MACE), major adverse limb events (MALE), and composite bleeding outcomes.
Results
Among 5,300 stable LEAD patients, of whom 844 received cilostazol alone, 1,786 received aspirin or clopidogrel, and 2,670 received cilostazol combined with aspirin or clopidogrel. After IPTW, there were no significant differences between cilostazol monotherapy and any antiplatelet therapy groups regarding MACE, MALE, or composite bleeding outcomes (aHR [95% CI] = 0.84 [0.68–1.03], p = 0.09; 0.84 [0.70–1.01], p = 0.06; 0.88 [0.71–1.10], p = 0.26, respectively). In secondary outcomes, cilostazol treatment was associated with a reduced rate of subsequent angioplasty (aHR [95% CI] = 0.80 [0.60–0.98], p = 0.03). There were no significant differences in clinical outcomes when comparing cilostazol monotherapy to cilostazol combined with antiplatelet therapy.
Conclusion
In this real-world Asian cohort, cilostazol showed similar prognostic benefits and safety compared to standard antiplatelet therapy. These findings support its role in the long-term management of LEAD patients following PTA, particularly in Asian populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Division of Cardiology, Department of Internal Medicine, Chung-Shan Medical University Hospital, School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
ORCID-Profile: Yi-Heng Li
Förderung
- Chung Shan Medical University Hospital
Zitieren
APA
Chang, H. Y., Lin, H. W., Chen, P. W., Lin, S. H., Chao, T. H., & Li, Y. H. (2025). Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty: A real-world analysis. PLOS One. https://doi.org/10.1371/journal.pone.0330434
Vancouver
Chang HY, Lin HW, Chen PW, Lin SH, Chao TH, Li YH. Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty: A real-world analysis. PLOS One. 2025. doi:10.1371/journal.pone.0330434
BibTeX
@article{Chang2025,
author = {Chang, Hsien-Yuan and Lin, Hui-Wen and Chen, Po-Wei and Lin, Sheng-Hsiang and Chao, Ting-Hsing and Li, Yi-Heng},
title = {Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty: A real-world analysis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0330434}
}
EUVIMED